VCU engineering professor receives $5 million grant to drive down costs of two key AIDS drugs

vcu-logoA Virginia Commonwealth University engineering professor has received a $5 million grant to develop a more cost-effective way to manufacture two important drugs used to treat HIV and AIDS.

“Our overarching goal is to increase the availability of these drugs,” said B. Frank Gupton, Ph.D., a professor in the VCU School of Engineering and chair of the Department of Chemical and Life Science Engineering. “There’s a finite amount of funds available to purchase these drugs, but if we can reduce the cost then we can increase the availability.”

The grant, which was awarded by the Bill & Melinda Gates Foundation, supports a multidisciplinary project led by Gupton called the Medicine for All Initiative, which seeks cheaper and more efficient ways to manufacture drugs, particularly those needed to treat HIV and AIDS in developing countries. The project is being conducted in partnership with the Clinton Health Access Initiative and collaborators at MIT and the University of Washington.

As part of the 18-month grant, Gupton’s team will find ways to drive down the costs of manufacturing the AIDS drugs tenofovir and darunavir. Darunavir is known as a second-line therapy and is often prescribed once a patient develops a resistance to first-line therapies.

“Over the lifetime of a HIV-infected patient, they may develop resistance. So they need to have these other drugs available as a backup,” Gupton said. “But the problem …[with] second-line treatments [like darunavir is] the volume of supply can sometimes be smaller and so they can be prohibitively expensive for many patients.”

The grant follows an earlier $4.4 million grant from the Gates Foundation in support of Gupton’s work to reduce the manufacturing cost of nevirapine, a first-line therapy for the treatment of AIDS.

In January, Gupton announced that his team has successfully developed a much more cost- effective way to produce the starting materials of nevirapine, thereby allowing pharmaceutical manufacturers to produce greater quantities of the drug, and expanding access in the countries that need it most, such as South Africa.

“The focus is on the global economy,” Gupton said. “It’s not as big of an issue here in the United States from the standpoint of infected patients, but the rate of infection is still growing [globally] at a rate of about 14 percent a year. So, particularly in these other emerging economies, it’s a real issue.”

Barbara D. Boyan, Ph.D., dean of the School of Engineering, said the school is proud of the innovative work being done by the Medicine for All Initiative.

“The School of Engineering is proud of the Gupton team and its role in improving the health and welfare of not only Americans but also the global community,” she said. “Medicine for All is part of a larger VCU initiative in pharmaceutical engineering. We look forward to continuing the participation of our students’, faculty’s and staff’s expertise to this endeavor.”

Alongside Gupton, the project involves several collaborators across the country, including Timothy F. Jamison, Ph.D., chair of the Department of Chemistry at MIT, and Brian Marquardt, Ph.D., head of the Center for Process Analysis & Control at the University of Washington.

This new phase of the Medicine for All Initiative, Gupton said, builds on the project’s earlier success and demonstrates that the team is heading in the right direction.

“We are applying the same principles that we used with nevirapine for these new drug targets,” Gupton said. “The lesson that we’re taking away from our initial work is that we must be on the right track and this new investment from the foundation just reinforces that.”

The project, Gupton added, is already making an impact in the world.

“The really nice thing about this project is that from the time you come to a solution to a problem and when it actually gets implemented is a lot shorter than you often see in academia,” he said. “Part of that is because we have this network of the foundation and the Clinton Health Access Initiative that is facilitating these innovations and improvements out of our laboratory and into the marketplace.”

Books from AFP

2018-19 UVA Basketball Preview: Just $1.99 on Amazon!

UVA Basketball finished the 2017-18 season ranked at the top of the national polls. Augusta Free Press editor Chris Graham offers his insight and analysis on the 2018-19 'Hoos, breaking down the roster, the legacy of coach Tony Bennett, and how the loss to UMBC could fuel a run through March Madness next spring.

The Worst Wrestling Pay-Per-View Ever: Just $3.49 on Amazon!

Chris Graham offers a glimpse behind the curtain of the pro wrestling business in his new book, The Worst Wrestling Pay-Per-View Ever, the inside story of the 2011 Night of Legends, a live pay-per-view event featuring stars including WWE Hall of Famers Kevin Nash, "Hacksaw" Jim Duggan and The Rock 'n Roll Express that was met with almost universally negative reviews.

Mad About U: History of University Hall available on Amazon for just $5.99!

Mad About U: Four Decades of at University Hall is a comprehensive book covering the players, coaches and memories of University Hall at the University of Virginia. Join us as we look back at the memories from more than 40 years in U Hall.

News From Around the Web

Shop Google